Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:ENSCNASDAQ:FRTXNASDAQ:JAGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.19+1.6%$0.16$0.12▼$3.39$1.55M-0.051.02 million shs16,897 shsENSCEnsysce Biosciences$2.38+1.7%$2.30$1.62▼$14.67$5.64M0.97942,682 shs77,921 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsJAGXJaguar Health$4.06+4.1%$6.46$3.75▼$110.75$2.74M0.9449,404 shs64,600 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+1.60%+11.76%+7.10%+5.85%-94.03%ENSCEnsysce Biosciences+1.71%+8.68%+14.81%-52.59%-71.62%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+6.12%JAGXJaguar Health+4.10%-5.80%-63.09%-71.85%-95.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path2.4959 of 5 stars3.53.00.00.02.50.01.3ENSCEnsysce Biosciences0.0217 of 5 stars0.02.00.00.00.00.00.0FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Health2.1331 of 5 stars3.55.00.00.01.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0010,426.32% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AJAGXJaguar Health 3.00Buy$60.001,377.83% UpsideCurrent Analyst Ratings BreakdownLatest BPTH, FRTX, JAGX, and ENSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AENSCEnsysce Biosciences$2.23M2.53N/AN/A($3.10) per share-0.77FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56JAGXJaguar Health$11.55M0.24N/AN/A$4.02 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/21/2025 (Estimated)ENSCEnsysce Biosciences-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AJAGXJaguar Health-$41.30MN/A0.00N/AN/A-360.13%-326.62%-67.02%8/12/2025 (Estimated)Latest BPTH, FRTX, JAGX, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025JAGXJaguar Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million3/10/2025Q4 2024ENSCEnsysce Biosciences-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86ENSCEnsysce BiosciencesN/A3.243.24FRTXFresh Tracks TherapeuticsN/AN/AN/AJAGXJaguar Health1.651.841.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%ENSCEnsysce Biosciences5.63%FRTXFresh Tracks Therapeutics25.04%JAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%ENSCEnsysce Biosciences7.90%FRTXFresh Tracks Therapeutics0.23%JAGXJaguar Health0.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableENSCEnsysce Biosciences102.37 million1.20 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableJAGXJaguar Health50674,00011.80 millionNo DataBPTH, FRTX, JAGX, and ENSC HeadlinesRecent News About These CompaniesJaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight SeriesJune 6 at 9:00 AM | accessnewswire.comJaguar Health (NASDAQ:JAGX) Rating Increased to Hold at Wall Street ZenMay 31, 2025 | americanbankingnews.comJaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 21, 2025 | accessnewswire.comFirst Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)May 20, 2025 | accessnewswire.comFirst Berlin Initiates Coverage of Jaguar Health (JAGX) with Buy RecommendationMay 20, 2025 | msn.comJaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comJaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 FinancialsMay 16, 2025 | finanznachrichten.deJaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ...May 16, 2025 | finance.yahoo.comJaguar Health, Inc. (JAGX) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comJaguar Animal Health Executes Stock Exchange AgreementsMay 15, 2025 | tipranks.comJaguar Health Reports First Quarter 2025 FinancialsMay 15, 2025 | accessnewswire.comJaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate UpdatesMay 14, 2025 | accessnewswire.comJaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and DogsMay 8, 2025 | accessnewswire.comJaguar Health Provides Overview of 2025 Crofelemer-Related CatalystsMay 7, 2025 | accessnewswire.comProof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure PatientsApril 30, 2025 | accessnewswire.comREMINDER: Jaguar Health Hosting April 30 Investor…April 29, 2025 | pharmiweb.comREMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)April 29, 2025 | accessnewswire.comJaguar Health’s Napo reports preliminary results from IIT trial of crofelemerApril 17, 2025 | markets.businessinsider.comProof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI CongressApril 17, 2025 | accessnewswire.comJaguar Health to present results from OnTarget study in breast cancer patientsApril 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, FRTX, JAGX, and ENSC Company DescriptionsBio-Path NASDAQ:BPTH$0.19 +0.00 (+1.60%) As of 06/6/2025 03:47 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Ensysce Biosciences NASDAQ:ENSC$2.38 +0.04 (+1.71%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.43 +0.05 (+1.93%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Jaguar Health NASDAQ:JAGX$4.06 +0.16 (+4.10%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.00 -0.05 (-1.35%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
